Loading...
MTAA
DIA
Market cap4.43bUSD
Aug 03, Last price  
75.16EUR
1D
4.59%
1Q
21.42%
Jan 2017
33.62%
IPO
528.43%
Name

DiaSorin SpA

Chart & performance

D1W1MN
MTAA:DIA chart
P/E
25.84
P/S
3.37
EPS
2.91
Div yield, %
1.67%
Shrs. gr., 5y
0.31%
Rev. gr., 5y
6.28%
Revenues
1.20b
+0.84%
179,756,000202,324,000244,612,000304,129,000404,547,000440,003,000433,763,000434,849,000443,770,000499,181,000569,312,000637,487,000669,197,000706,319,000881,305,0001,237,654,0001,361,138,0001,148,210,0001,185,000,0001,195,000,000
Net income
156m
-17.27%
22,294,00025,219,00037,459,00070,047,00090,418,00099,607,00087,396,00083,028,00084,074,000100,420,000112,383,000139,878,000158,128,000175,735,000247,871,000310,968,000240,907,000159,849,000188,105,000155,624,000
CFO
343m
-4.47%
33,976,00030,348,00047,779,00064,219,00095,791,000108,578,000110,582,000107,717,000119,847,000138,449,000165,597,000167,440,000209,879,000232,670,000304,562,000400,664,000389,341,000311,663,000358,782,000342,760,000
Dividend
May 18, 20261.3 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
URL
https://www.diasorin.com/
IPO date
Jul 19, 2007
Employees
3,278
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT